We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
3d
Zacks Investment Research on MSNGilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on ItGilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...
2d
Barchart on MSNGilead Sciences - Leader in HIV MedicinesYour FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...
([content-module:CompanyOverview, NASDAQ:GILD) Gilead Sciences Inc. (NASDAQ:GILD) stock surged to a new 52-week high at $106.69 recently on its fourth quarter of 2024 earnings release. After being ...
Gilead Sciences, Inc. (NASDAQ:GILD) is still seeing strong product revenue growth regarding its Covid-19 anti-viral drug Veklury [remdesivir]. This is because in the company's Q3 of 2024 financial ...
Gilead Sciences Inc (Symbol: GILD) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a stunning $22.93B worth of stock held by ETFs, and above-average ''DividendRank'' statistics ...
Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...
Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results, a robust HIV franchise, and an imminent lenacapavir commercialization by summer 2025. Lenacapavir PrEP regimen, with 100% ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
FOSTER CITY, Calif., February 24, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...
Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results